James K Godfrey
Overview
Explore the profile of James K Godfrey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tumuluru S, Godfrey J, Cooper A, Yu J, Chen X, MacNabb B, et al.
Blood
. 2025 Jan;
PMID: 39869833
Most diffuse large B-cell lymphoma (DLBCL) patients treated with immunotherapies such as bispecific antibodies (BsAb) or chimeric antigen receptor (CAR) T cells fail to achieve durable treatment responses, underscoring the...
2.
Godfrey J, Gao L, Shouse G, Song J, Pak S, Lee B, et al.
Blood
. 2024 Mar;
144(4):457-461.
PMID: 38484137
Although CD20×CD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in central nervous system (CNS) lymphoma is unknown. Here, we report the CD20×CD3 bispecific glofitamab penetrates the blood-brain...
3.
Tumuluru S, Godfrey J, Cooper A, Yu J, Chen X, MacNabb B, et al.
bioRxiv
. 2024 Feb;
PMID: 38328071
Most diffuse large B-cell lymphoma (DLBCL) patients treated with bispecific antibodies (BsAb) or chimeric antigen receptor (CAR) T cells fail to achieve durable treatment responses, underscoring the need for a...
4.
Cooper A, Tumuluru S, Kissick K, Venkataraman G, Song J, Lytle A, et al.
J Clin Oncol
. 2023 Dec;
42(4):467-480.
PMID: 38079587
Purpose: A genetic classifier termed LymphGen accurately identifies diffuse large B-cell lymphoma (DLBCL) subtypes vulnerable to Bruton's tyrosine kinase inhibitors (BTKis), but is challenging to implement in the clinic and...
5.
Godfrey J, Nabhan C, Karrison T, Kline J, Cohen K, Bishop M, et al.
Cancer
. 2019 Feb;
125(11):1830-1836.
PMID: 30707764
Background: Dual translocation of MYC and BCL2 or the dual overexpression of these proteins in patients with aggressive B-cell lymphomas (termed double-hit lymphoma [DHL] and double-expressor lymphoma [DEL], respectively) have...